Published 13 July 2016
E-Rare – the ERA-net for research programmes on rare diseases – has opened a joint call to promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or having achieved a significant stage in the development process in rare indications.
E-Rare encourages the use of European health research infrastructures, such as EATRIS to deliver on specific services.
EATRIS services encompasses among others:
- In vivo imaging-enabled drug development, supporting pre-clinical and clinical assessment of target expression, modulation and internalisation, drug pharmacokinetics and biodistribution, normal organ uptake, optimisation of drug dose & scheduling, and assessment of inter-patient variation;
- Drug (re-) formulation expertise, access to an array of drug delivery technologies;
- Access to a wide array of specialised pre-clinical models, as well as clinical expertise and patient cohorts for many rare diseases.
More information: http://www.erare.eu/joint-call/e-rare-3-call-proposals-2016-jtc-2016-clinical-research-new-therapeutic-uses-already-0
